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on cardiac endpoints would address the knowledge gap 
about the effects of different omega-6 PUFA intakes on the 
risk of heart disease.  Copyright © 2011 S. Karger AG, Basel 
 A lively, impassioned debate about healthy fats for 
healthy hearts was held on May 31, 2010, in conjunction 
with the biennial meeting of the International Society for 
the Study of Fatty Acids and Lipids (ISSFAL), Maastricht, 
The Netherlands, from May 29 to June 2, 2010. The de-
bate was organized for ISSFAL by the International Ex-
pert Movement (IEM), a group of experts committed to 
improving everyone’s dietary fat quality. The activities of 
the IEM are funded by an unrestricted educational grant 
from Unilever NV under the auspices of the Internation-
al Union of Nutritional Sciences.
 The two-part debate, chaired by Prof. Berthold Ko-
letzko, Ludwig Maximilian University, Germany, ad-
dressed the following propositions:
 • reduction of saturated fat is an important element of 
dietary change in the primary prevention of coronary 
heart disease (CHD) at the population level; 
 • the consumption of at least 5–10% of energy from 
omega-6 polyunsaturated fatty acids (PUFAs) reduces 
the risk of CHD relative to lower intakes.  
 Key Words 
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 Abstract 
 Background/Aims: The importance of reducing saturated 
fatty acid intake to prevent cardiovascular disease and rec-
ommended intakes for omega-6 polyunsaturated fatty acids 
(PUFAs) are controversial. Therefore, experts debated these 
topics at the biennial meeting of the International Society 
for the Study of Fatty Acids and Lipids (ISSFAL), in May 2010. 
 Methods: Debate transcripts, debaters’ and discussants’ re-
views and literature citations were the basis of this report. 
 Results:  Participants agreed that saturates per se are not 
‘bad’, but that dietary recommendations should emphasize 
the substitution of unsaturates for part of the saturates. Evi-
dence supporting omega-6 PUFA intakes of 5 to 10% is 
mixed; some interpret the overall data from diverse studies 
as consistent with a reduction in the risk of cardiovascular 
mortality and events. Others assert that randomized con-
trolled trial data suggest that higher intakes of omega-6 
PUFAs are not associated with lower risk of heart disease, or 
may even increase it.  Conclusions: All agreed that a 5-year 
randomized controlled trial comparing the effects of histor-
ically low (2%) with currently high (7.5%) linoleic acid intakes 
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 Discussing the first statement were Profs. Bruce Ger-
man, University of California, USA, and Ricardo Uauy, 
University of Chile, Chile, and London School of Hygiene 
and Tropical Medicine, UK.
 Opening the debate, Prof. German asserted that satu-
rated fat is a ‘highly functional fat’, meaning that it is the 
most delicious, luxurious and pleasant sensation in one’s 
mouth. As a result, saturated fats migrated into the food 
supply and changed the food supply itself. Saturated fat 
comes in different places, Prof. German said, the most 
obvious being lactation. For over 100 million years, mam-
malian mothers have produced milk with approximately 
30% of total fatty acids as saturated fat, for the presumed 
benefit of their young  [1] . This long-term conservation of 
saturated fatty acids in milk demonstrates the impor-
tance of saturated fats to the evolution of mammals, in-
cluding humans  [2] . What saturated fat is combined with 
today has much more influence on human health than 
saturated fat itself. Nonetheless, the question is: does con-
sumption of bovine milk and dairy products result in 
 increased levels of heart disease in the population? Prof. 
German then mentioned the work of Peter Elwood, who 
reported that saturated fats consumed  as dairy are associ-
ated with a  reduction in risk of ischemic heart disease, 
stroke, all-cause mortality and incident diabetes  [3] . Sat-
urated fat is not a toxin, Prof. German said. It functions 
as a signalling molecule that, unlike PUFAs, activates the 
synthesis of cholesterol and other lipids for the produc-
tion of very-low-density lipoprotein particles, thereby 
providing fuel for physiological processes like exercise, 
lactation, infant growth and fighting infections  [4–6] . 
This implies that saturated fat has a metabolic value. 
However, 50-year-old men who are sedentary, over-
weight, cannot lactate, do not exercise and have no infec-
tious disease do not benefit from greater cholesterol syn-
thesis and, therefore, may not be the appropriate refer-
ence point for dietary recommendations. Data show that 
saturated fat in a subset of the population can even be 
protective of heart disease  [7] . Very high intakes of any 
substance, including saturated fat, are deleterious, mod-
erate intakes mostly not. Prof. German concluded that 
dietary recommendations need to be based on the indi-
vidual’s need and on each person’s metabolic response.
 Prof. Uauy rebutted Prof. German’s arguments by de-
claring that the discussion is not about ridding the diet of 
saturated fat because it is toxic. It is  not. It was a mistake 
to recommend cutting down total fat intake. The discus-
sion is about reducing one fat and replacing it with a 
healthier one. We often generalize about saturated fats, 
Prof. Uauy said, but we should understand that not all sat-
urated fats are the same. For example, the biology of stea-
ric acid is very different from that of the C12, C14, and C16 
saturated fatty acids  [8, 9] . Foods contain a combination 
of fatty acids; milk might be good, something else not. We 
cannot lump all saturated fats together, but should be talk-
ing about reducing those saturated fats that raise the ratio 
of low- to high-density lipoproteins (LDL:HDL). The issue 
is complicated by different fat matrices and by  trans fatty 
acids. The aim is not to lower total fat intake but to replace 
part of the dietary saturated fatty acids  not with refined 
carbohydrate  [10–12]  nor with  trans  fatty acids  [13] but 
with (poly)unsaturated fatty acids  [14] that favorably af-
fect the LDL:HDL cholesterol ratio, as supported by abun-
dant evidence  [15, 16] . Prof. Uauy also highlighted results 
from Finland, which demonstrated that diet counselling 
of parents and their children was successful in reducing 
saturated fat intake and plasma cholesterol levels and im-
proving additional cardiovascular risk markers  [17] .
 In a brief reaction, Prof. German again challenged the 
view that saturated fats are bad; this would imply the 
public health assumption that the status quo – seden-
tary, overweight, inactive men – are the inexorable future 
of the human condition. Prof. German believes that we 
should aim for an ‘active, playful society’ where saturated 
fats ‘in moderation, of course, will be an important part 
of every diet’.
 Prof. Uauy responded that today’s reality requires that 
we act now to fight obesity (which is on the rise) and 
CHD, which is still the main killer. Increasing physical 
activity and replacing at least part of the cholesterol-rais-
ing saturates by (poly)unsaturates are essential changes 
we need to accept. ‘Do what is best for most individuals’, 
he said, and ‘start early in life’.
 A comment by Dr. Pedro Bastos, University of Lund, 
Sweden, noted that in some non-westernized populations 
myocardial infarction, stroke, metabolic syndrome and 
obesity are rare  [18, 19] . Yet these groups obtain about 
17% of their calories from saturated fat  [20] . We also have 
the Masai, Dr. Bastos continued, who rely for their nutri-
tion mostly on milk, blood and meat and hence consume 
large amounts of saturated fat. Nonetheless, they have 
low serum cholesterol levels, and although they have cor-
onary atherosclerosis their hearts are small and their cor-
onary vessels actually enlarge with age, so that the lumi-
na are not compromised by intimal thickening  [21] .
 Prof. Uauy agreed that if we were as active as the Masai 
we wouldn’t need to change our diet. But we are  not . Un-
til we change our physical inactivity, he repeated, we have 
to stay with the facts and replace at least part of the di-
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 Prof. Gerald Reaven, Stanford University, USA, noted 
that there are at least two major metabolic abnormalities 
that can lead to cardiac disease. One is an elevated plasma 
concentration of LDL cholesterol. This situation is con-
trolled mostly by genes  [22–24] , with relatively modest 
ability to change by the amount or kind of fat  [25] . None-
theless, saturated fat reduction should be applied to lower 
LDL cholesterol, he added. In contrast, heart disease can 
also be based on a different metabolic abnormality char-
acterized by insulin resistance, high insulin levels, high 
triglycerides and low HDL cholesterol concentrations. 
This is often the case in South Asian Indians  [26–28] . In 
general, replacement of saturated fat by carbohydrate 
raises insulin and triglyceride concentrations and lowers 
HDL cholesterol levels  [10, 12, 29] . Consequently, this will 
increase the risk of CHD. Prof. Reaven concluded that 
saturated fat replacement can contribute to lowering 
CHD risk, but the crucial question is: what does one re-
place it with? Replacement by carbohydrate is often not 
the best option.
 Profs. German and Uauy fully agreed that genetics, 
diet and lifestyle should be the basis for recommenda-
tions to reduce cardiovascular risk. There is no reason to 
lower the dietary fat  content , but the  composition should 
be optimized, they concluded.
 Dr. Apostolos Pappas, Johnson & Johnson, USA, com-
mented on the difficulty in making the right dietary rec-
ommendations because of lifestyle differences within the 
population. Vegetarians and vegans, for instance, can 
hardly be advised to lower their saturated fat intake be-
cause that intake is pretty low already  [30, 31] . Dr. Pappas 
advocated a focus on balancing the different types of di-
etary fats by using numerical ranges or ratios in dietary 
recommendations. The truth lies in the middle, he con-
cluded, not in the extremes.
 A final comment came from Prof. Birgitta Strandvik, 
Karolinska Institutet, Sweden, who described the absence 
of obesity and insulin resistance in the offspring of mice 
which were given a high saturated fat diet nearly free 
from essential fatty acids during pregnancy and lactation 
 [32] . These results confirm the experience in former 
Scandinavian generations who had a very high saturated 
fat intake, but their children were usually not obese  [33] . 
Referring to the work of Lands  [34] , Prof. Strandvik con-
cluded that a high saturated fat intake together with small 
amounts of essential fatty acids might be preferred, espe-
cially during lactation.
 Prof. William Harris, University of South Dakota, 
USA, and Dr. Christopher Ramsden, National Institutes 
of Health, USA, engaged the second proposition about 
consuming at least 5–10% energy from omega-6 PUFAs 
to reduce the risk of CHD. The statement is based on 
a recent scientific advisory from the American Heart 
 Association (AHA), published by Harris et al.  [35] . The 
AHA examined different types of evidence in humans to 
assess the relationship between omega-6 PUFA intakes 
and cardiovascular disease. Studies included ecological 
and retrospective case-control studies, meta-analyses of 
randomized trials with physiologic measures of risk fac-
tors (blood lipoprotein levels), prospective cohort studies 
and randomized trials with clinical endpoints (myocar-
dial events or cardiovascular deaths).
 The ecological  [36] and retrospective observational 
 [37] data presented were consistent with the thesis that 
higher intakes of linoleic acid (LA) were associated with 
a lower risk of CHD. In the latter study  [37] , LA appeared 
to be an even more powerful predictor than eicosapen-
taenoic acid and docosahexaenoic acid. However, Prof. 
Harris emphasized that associations do not establish 
cause.
 Of the studies providing stronger scientific evidence, 
Prof. Harris cited a meta-analysis of 60 randomized trials 
on omega-6 PUFA consumption and total, LDL, and 
HDL cholesterol levels. The greatest reduction in the ratio 
of total to HDL cholesterol was observed in those with the 
highest intakes of omega-6 PUFAs  [38, 39] . Comparable 
results were obtained in a pooled analysis of 11 observa-
tional trials on incident CHD: for a 5% lower energy in-
take from saturated fatty acids and a concomitant higher 
energy intake from PUFAs, there was a significant reduc-
tion in risk of coronary events and mortality  [15] .
 A meta-analysis of randomized trials in which part of 
the saturated fatty acids was replaced by PUFAs report-
ed a significant 19% pooled risk reduction in cardiovascu-
lar mortality and events with increased consumption of 
 PUFAs from an average of 5% to 15% energy  [16] . It was 
recognized that fatty acid substitution or replacement 
studies cannot prove that the replaced fatty acid was re-
sponsible for the observed effect because what was re-
placed was also reduced. Prof. Harris finished by drawing 
attention to a recent narrative review from France, con-
cluding that a recommended intake of omega-6 PUFAs 
above 5%, and ideally about 10% of total energy, appears 
justified  [40] .
 Challenging the AHA advisory, Dr. Ramsden cited the 
case of hormone replacement therapy (HRT) as an ex-
ample of the potential hazards of basing recommenda-
tions on prospective cohort observational studies. HRT 
use has been consistently associated with reduced CHD 
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association was tested for causality in a randomized con-
trolled  trial,  HRT   caused  substantial  increases  in  risks 
of CHD and death  [43, 44] . Dr. Ramsden, therefore, con-
centrated his remarks on randomized controlled trials, 
which constitute the critical evidence base for the ome-
ga-6 PUFA recommendations, as also emphasized by 
Prof. Harris  [45, 46] .
 Dr. Ramsden noted a shift in the AHA advisory from 
the non-specific term ‘PUFA’ when discussing random-
ized trials, to the more specific term ‘omega-6 PUFA’ in 
making recommendations  [35] . This imprecision in de-
fining the terms ‘PUFA’ and ‘omega-6 PUFA’ overlooks 
the inclusion of omega-3 PUFAs. An extreme example of 
the contribution of omega-3 PUFAs to the total PUFA 
consumption is the Oslo Diet Heart Study  [47, 48] , which 
Dr. Ramsden described as ‘a multiple-intervention trial 
masquerading as an omega-6 PUFA trial’ because it had 
additional dietary changes.
 He also noted that the meta-analysis of Mozaffarian et 
al.  [16] contained 5 trials that were based on multiple in-
terventions, including  trans fatty acid replacement and 
increased omega-3 PUFA consumption. After eliminat-
ing those and including 2 additional studies not men-
tioned by Mozaffarian et al., 3 trials (4 data sets) specific 
to omega-6 PUFAs were available  [49–51] . A meta-analy-
sis of these data demonstrated that higher intake of ome-
ga-6 PUFAs was associated with a 3–17%  greater risk of 
nonfatal myocardial infarction, cardiac death, or CHD 
risk and a nearly 16% higher risk of all-cause mortality 
(p   6 0.12). From this analysis  [52] , Dr. Ramsden con-
cluded that the consumption of 5–10% omega-6- specific 
 PUFAs does not reduce the risk of CHD.
 Only one trial, the Lyon Diet Heart Study, examined 
the effect of consuming less than 5% omega-6 PUFAs 
 [53] . As part of a multiple intervention to mimic the Med-
iterranean diet, LA consumption was reduced to less than 
4% and   -linolenic acid intake increased to 0.8%. After a 
27-month follow-up, there was a 70% reduction in total 
mortality  and  a  73%   reduction   in   total   cardiac   events 
in the treatment group  [54] . This study ‘unequivocally 
showed that high or moderate LA diets are not necessary 
for profound CHD risk reduction’, Dr. Ramsden said.
 He concluded that the available controlled trials pro-
duce no basis for population-wide recommendations to 
increase omega-6 PUFA consumption and stated that a 
randomized controlled trial comparing the effects of a 
low ( ! 2%) with a high ( 1 7%) LA diet on clinical CHD 
outcomes is ‘long overdue’.
 In response, Prof. Harris acknowledged that the ran-
domized controlled trials discussed in the AHA advisory 
were not perfect; therefore, the committee relied on vari-
ous types of evidence, some of which were not discussed 
so far. As an example, he mentioned that certain omega-6 
PUFAs give rise to some powerful vasodilatory, anti-
platelet and anti-inflammatory compounds, e.g. lipoxins 
and prostacyclin. He noted that although controlled trials 
are not perfect, the totality of evidence supports the view 
that more omega-6 PUFAs are probably better than less. 
We don’t know what’s happening at a level of 2% LA, he 
added, but expressed doubt about the funding potentials 
of a trial to find out.
 Dr. Ramsden noted that results from prospective co-
hort observational studies are extremely weak because 
they are often based on food frequency questionnaires. In 
his view, these questionnaires cannot reliably disentangle 
the respective intakes of LA and   -linoleic acid. He urged 
the AHA to fund a randomized trial with a high oleic 
versus a high linoleic variety of sunflower or safflower oil 
with the same background diet.
 Prof. Bill Lands (retired, National Institutes of Health, 
USA) strongly advised the scientific community to con-
duct scientific discussions only on the basis of data and 
facts and to maintain collegiality and openness although 
many fellow scientists compete for the same grants.
 Dr. Bastos indicated that in India  [55] and Israel  [56] 
omega-6 PUFA consumption is very high and so is the 
rate of CHD. Of course, this does not show causality, he 
added, but it illustrates the need for a randomized con-
trolled trial as suggested by Dr. Ramsden and supported 
by Prof. Harris.
 Dr. Joe Hibbeln (National Institutes of Health, USA) 
referred to the work of Prof. Lands and others showing 
that reduction of dietary LA below 4% results in consid-
erable increases in plasma or erythrocyte eicosapentae-
noic acid or docosahexaenoic acid concentrations with-
out additional intakes  [57–59] . Dr. Ramsden later added 
that overabundant LA can also compete for esterification 
with other PUFAs, as illustrated by the nearly 50% reduc-
tion in arachidonic acid levels in coronary atheroma 
phospholipids obtained from subjects on a high (15%) as 
compared to a low (4%) linoleate diet in the LA Veterans 
Trial  [60] . Similar conclusions regarding competition for 
esterification can be drawn from the negative correlation 
of LA with all highly unsaturated fatty acids in red-cell 
phospholipids of pregnant women  [61] .
 Dr. Hibbeln also pointed out that humans evolved on 
a diet of 1–2% linoleate for five million years or more  [62, 
63] . Now we consume about 8% linoleate  [64] . In mice, 
increasing the LA intake from 1 to 8% caused a doubling 
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cerol  [65] , which mediates increased food consumption 
and adiposity  [66, 67] . If obesity predicts heart disease, 
Dr. Hibbeln added, one has to consider that the high-LA 
diets advocated by the AHA advisory may flood the 
brain, increase appetite and food intake, contribute to 
obesity and, ultimately, could promote heart disease.
 Prof. Harris intervened that no significant relation-
ship has yet been reported between LA intake and obe-
sity in humans  [68] , but Dr. Ramsden responded that this 
is probably due to the saturation of all relevant enzymes 
at present LA intakes above 4%  [69, 70] .
 Dr. Peter Zock (Unilever, The Netherlands) supported 
Prof. Lands’ appeal to stay with the facts. Although he 
considered Dr. Hibbeln’s comment on linoleate and en-
docannabinoids inspirational, he felt they do not repre-
sent human data. He also expressed his admiration for 
the figures shown by Dr. Ramsden on the fatty acid com-
positions of the various trial diets, but based on his own 
experience with similar calculations he had to conclude 
that such figures are often guesses rather than facts. Dr. 
Ramsden responded by demonstrating that the disputed 
nutrient intakes in his figures were extracted from the 
published methods papers of the Oslo  [48] and Lyon  [53] 
Diet-Heart studies. Finally, when asked by Dr. Zock about 
the potential importance of omega-6 PUFAs for reducing 
LDL cholesterol and, consequently, CHD risk, Dr. Rams-
den replied that lowering LDL cholesterol sometimes 
lowers CHD  [71, 72] and sometimes does not  [73, 74] . He 
also stipulated that LDL cholesterol is just one factor in-
volved in heart disease. The omega-3 index is another  [75] 
and this index is reduced by dietary LA  [58, 59] . So, the 
most relevant health aspects of raising dietary linoleate 
above 5% are uncertain and become a matter of opinion 
rather than fact, Dr. Ramsden concluded. 
 Prof. Uauy noted an unsettled issue of great impor-
tance: the need for data comparing the effects of omega-3 
PUFAs at varying backgrounds of omega-6 PUFAs. Until 
there are new data to sort this out, we should be cautious 
in defining recommendations, he stated. There was also 
a suggestion from the floor that AHA withdraw its advi-
sory statement, to which Prof. Harris responded that he 
was all for more data, but in his opinion AHA would be 
unlikely to withdraw the statement. The debate conclud-
ed with agreement by all that we need a randomized con-
trolled trial to compare the effect of low and high intakes 
of LA. The trial should have typical US intakes of ome-
ga-3 PUFAs, with 7.5% energy from LA (the current US 
intake) in one group and 2.0% LA (historical intake) in 
the other. It would study cardiac endpoints and continue 
for about 5 years.
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